Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies

Author(s): Vincenzo Emanuele Chiuri, Nicola Silvestris, Andrea Tinelli and Vito Lorusso

Affiliation: Oncologia Medica, Ospedale ‘V. Fazzi’, P.zza F. Muratore, 73100 Lecce, Italy.


Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most significant clinical trials evaluating different combinations and schedules of docetaxel plus biological therapeutics.

Keywords: Docetaxel, targeted therapy, solid tumors, EGFR, PDGFR, VEGFR, RTKI, BCL-2, safety, efficacy

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [982 - 1000]
Pages: 19
DOI: 10.2174/138945009789578007
Price: $58